There was no association between the duration of statin therapy and changes in plasma leptin levels .
Furthermore , there was no differential effect of hydrophilic and lipophilic statins on plasma leptin concentrations .
OBJECTIVES The effects of statins on insulin sensitivity , metabolic homeostasis and adipokines in humans are controversial .
Several studies have investigated the impact of statin therapy on plasma leptin concentrations but the results have been inconsistent .
The aim of the present study was to conduct a systematic review and meta- analysis of available evidence to calculate the effect size of statin therapy in changing serum leptin concentrations .
Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients.
BACKGROUND The effect of statins on insulin resistance is controversial and poorly studied in nondiabetic subjects . In addition , the effect of statins on leptin and adiponectin has never been studied . METHODS Forty healthy nondiabetic volunteers ( 22 men and 18 women ) aged 28 to 72 were r and omized either to placebo or pravastatin 40 mg daily for a 12-week period . Insulin resistance , assessed using the Quantitative Insulin Sensitivity Check Index ( QUICKI ) , as well as serum leptin and adiponectin levels , was measured at baseline and at the end of therapy . RESULTS Pravastatin treatment decreased total cholesterol , low-density lipoprotein cholesterol , and triglycerides levels by 24 % , 32 % , and 14 % , respectively ( P < .05 for all ) , but did not affect glucose and insulin levels , the ( QUICKI ) index , and adiponectin and leptin levels . When stratification was performed according to QUICKI index or sex , no significant differences were observed in the prevalues and postvalues of leptin , adiponectin , or QUICKI index in the pravastatin group . Adiponectin , leptin , and QUICKI index were statistically higher in women than in men ( P < .001 for both variables ) . Adiponectin was negatively correlated with body mass index ( BMI ; r = -0.39 , P < .05 ) and positively correlated with the QUICKI index ( r = 0.54 , P < .001 ) and with high-density lipoprotein cholesterol ( r = 0.50 , P < .01 ) . The relation between adiponectin and QUICKI index remained significant after adjustment for sex and BMI ( P = .005 and P = .007 , respectively ) . Leptin was only related to BMI ( r = 0.57 , P < .001 ) and to sex ( P < .001 ) with no significant correlations with lipid parameters or QUICKI index . Both sex and BMI are independent predictors of leptin ( P < .001 and P < .001 ) . CONCLUSION A 12-week treatment with pravastatin 40 mg/d does not change the QUICKI index and leptin and adiponectin levels in healthy volunteers . In addition , our results emphasize the importance of sex and BMI in the determination of both adiponectin and leptin . Adiponectin was also related to QUICKI index , whereas this relation was not found with leptin
There was no association between the duration of statin therapy and changes in plasma leptin levels .
Furthermore , there was no differential effect of hydrophilic and lipophilic statins on plasma leptin concentrations .
OBJECTIVES The effects of statins on insulin sensitivity , metabolic homeostasis and adipokines in humans are controversial .
Several studies have investigated the impact of statin therapy on plasma leptin concentrations but the results have been inconsistent .
The aim of the present study was to conduct a systematic review and meta- analysis of available evidence to calculate the effect size of statin therapy in changing serum leptin concentrations .